Objective: Since FDA approval of deep brain stimulation (DBS) for essential tremor over 2 decades ago, indications and utilization of this modality have rapidly expanded worldwide. However, certain patient populations are known to be underrepresented among those undergoing DBS for various indications.
Methods: A systematic search was conducted using PubMed and Embase for disparities related to DBS care.
Objective: There is a scarcity of large multicenter data on how preoperative lumbar symptom duration relates to postoperative patient-reported outcomes (PROs). The objective of this study was to determine the effect of preoperative and baseline symptom duration on PROs at 90 days, 1 year, and 2 years after lumbar spine surgery.
Methods: The Michigan Spine Surgery Improvement Collaborative registry was queried for all lumbar spine operations between January 1, 2017, to December 31, 2021, with a follow-up of 2 years.
Objective: Osteoporosis has significant implications in spine fusion surgery, for which reduced spinal bone mineral density (BMD) can result in complications and poorer outcomes. Currently, dual-energy x-ray absorptiometry (DEXA) is the gold standard for radiographic diagnosis of osteoporosis, although DEXA accuracy may be limited by the presence of degenerative spinal pathology. In recent years, there has been an evolving interest in using alternative imaging, including CT and MRI, to assess BMD.
View Article and Find Full Text PDFWorld Neurosurg
August 2022
Background: Deep brain stimulation (DBS) is a pivotal surgical treatment for movement disorders. However, men and women have had differing opinions and referral experiences related to DBS, leading us to assess whether a gender disparity exists in the interval from a movement disorder diagnosis to DBS usage.
Methods: We performed a single-center, retrospective cohort study of 105 patients who had undergone DBS surgery for either Parkinson disease (PD) or essential tremor (ET).
Front Pain Res (Lausanne)
March 2022
Epilepsy is a neurological disorder that affects more than 70 million people globally. A considerable proportion of epilepsy is resistant to anti-epileptic drugs (AED). For patients with drug-resistant epilepsy (DRE), who are not eligible for resective or ablative surgery, neuromodulation has been a palliative option.
View Article and Find Full Text PDF